Clinical trial
A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate…
NCT00134966 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00134966 |
|---|---|
| Title | A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa |
| Official title | A 39 Week Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Effect of Fixed Dose Carbidopa/Levodopa/Entacapone 100 mg t.i.d. vs. Immediate Release Carbidopa/Levodopa 25/100 mg (t.i.d.) in Parkinson's Disease Patients Requiring Levodopa |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) |
| Enrollment | 493 |
| Start date | Aug 1, 2005 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Aug 25, 2005 |
| Last update posted | May 17, 2017 |
| Countries | Canada, Czechia, Israel, Italy, Poland, Portugal, Turkey (Türkiye), United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: